Vivos unites influential women leaders in medicine and dentistry to drive collaboration following first ever FDA 510(k) clearance of an oral device to treat severe OSA December 11, 2023 07:30 ET | Source: Vivos Therapeutics, Inc LITTLETON, Colo., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical…

With this unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new revenue opportunities for Vivos   LITTLETON, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and…

November 14, 2023 16:05 ET | Source: Vivos Therapeutics, Inc Follow Operating Expenses Decreased 32% Year Over Year and 19% Sequentially as Cost Cutting Measures Take Hold New Strategic Relationships, Including U.S. Nationwide Distribution Agreement with Lincare, Expected to Add Potentially Significant New Revenue Opportunities Management to Host Conference Call Today at 5:00…

Lincare to distribute Vivos oral appliances through an exclusive nationwide agreement October 24, 2023 07:30 ET | Source: Vivos Therapeutics, Inc Follow LITTLETON, Colo., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS a leading medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate…

Randomized controlled clinical trial using Vivos’ DNA Oral Appliance Therapy to study the DNA’s impact on OSA versus CPAP October 11, 2023 07:30 ET | Source: Vivos Therapeutics, Inc LITTLETON, Colo., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company") (NASDAQ: VVOS), a medical technology company focused on developing innovative…

October 05, 2023 07:30 ET | Source: Vivos Therapeutics, Inc Vivos Executes Distribution Agreement with Established Dubai-based Sleep Testing Company Subject to Regulatory Approvals, Vivos Could See Revenue From This Collaboration in 2024 LITTLETON, Colo., Oct. 05, 2023 (GLOBE NEWSWIRE) --  Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing…

New Relationships Expected to Add Potentially Significant New Revenue Opportunities for Vivos as well as Airway-Focused Expertise and Potential Cost Savings for Vivos-trained Providers October 04, 2023 07:30 ET | Source: Vivos Therapeutics, Inc LITTLETON, Colo., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and…

Vivos Attracts Wide Group of Experts in Dental and Medical Disciplines With a Shared Vision to Treat the Millions of Patients Suffering with Breathing-Related Sleep Disorders October 02, 2023 07:30 ET | Source: Vivos Therapeutics, Inc LITTLETON, Colo., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical…

August 16, 2023 16:05 ET | Source: Vivos Therapeutics, Inc Operating Expenses Decreased 31% Quarter Over Quarter and 25% Year to Date, Reflecting Cost Cutting Initiatives Management to Host Conference Call Today at 6:00 pm ET LITTLETON, Colo., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a medical technology company focused…

August 16, 2023 07:30 ET | Source: Vivos Therapeutics, Inc LITTLETON, Colo., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with…